Glycogen Synthase Kinase 3
"Glycogen Synthase Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycogen synthase kinase that was originally described as a key enzyme involved in glycogen metabolism. It regulates a diverse array of functions such as CELL DIVISION, microtubule function and APOPTOSIS.
| Descriptor ID |
D038362
|
| MeSH Number(s) |
D05.500.117.875 D08.811.913.696.620.682.700.429.500 D08.811.913.696.620.682.700.646.625 D12.644.360.300.500 D12.776.476.081.875 D12.776.476.300.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glycogen Synthase Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "Glycogen Synthase Kinase 3".
This graph shows the total number of publications written about "Glycogen Synthase Kinase 3" by people in this website by year, and whether "Glycogen Synthase Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 2 | 5 | 7 |
| 2004 | 6 | 3 | 9 |
| 2005 | 2 | 3 | 5 |
| 2006 | 0 | 3 | 3 |
| 2007 | 3 | 5 | 8 |
| 2008 | 9 | 3 | 12 |
| 2009 | 4 | 5 | 9 |
| 2010 | 3 | 9 | 12 |
| 2011 | 4 | 8 | 12 |
| 2012 | 2 | 5 | 7 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycogen Synthase Kinase 3" by people in Profiles.
-
?-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus. World J Gastroenterol. 2023 Jul 28; 29(28):4416-4432.
-
Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. Proc Natl Acad Sci U S A. 2023 04 18; 120(16):e2220134120.
-
The apoptotic effect of GSK-3 inhibitors: BIO and CHIR 98014 on H1975 lung cancer cells through ROS generation and mitochondrial dysfunction. Biotechnol Lett. 2020 Aug; 42(8):1351-1368.
-
Visual impairment and progressive phthisis bulbi caused by recessive pathogenic variant in MARK3. Hum Mol Genet. 2018 08 01; 27(15):2703-2711.
-
GSK-3 promotes S-phase entry and progression in C. elegans germline stem cells to maintain tissue output. Development. 2018 05 14; 145(10).
-
GSK-3 Inhibitors: A Double-Edged Sword? - An Update on Tideglusib. Drug Res (Stuttg). 2018 Aug; 68(8):436-443.
-
GSK-3 as a novel prognostic indicator in leukemia. Adv Biol Regul. 2017 08; 65:26-35.
-
Gestational Protein Restriction Impairs Glucose Disposal in the Gastrocnemius Muscles of Female Rats. Endocrinology. 2017 04 01; 158(4):756-767.
-
Correlative Studies Unravelling the Possible Mechanism of Cell Death in Tideglusib-Treated Human Ovarian Teratocarcinoma-Derived PA-1 Cells. J Environ Pathol Toxicol Oncol. 2017; 36(4):321-344.
-
Inorganic polyphosphate promotes cyclin D1 synthesis through activation of mTOR/Wnt/?-catenin signaling in endothelial cells. J Thromb Haemost. 2016 11; 14(11):2261-2273.